My Profile

Search abstracts

Lewis Sheiner


2019
Stockholm, Sweden



2018
Montreux, Switzerland

2017
Budapest, Hungary
   Program
   Organisers
   Abstracts
   Participants

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland

Printable version

 

Tuesday 6 June

 

14:00-18:00 Registration at the Conference Venue
       
19:00-22:00 Opening ceremony, welcome reception and dinner
       

 

Wednesday 7 June

 

08:00-08:45 Registration
       
08:45-09:00 Welcome and Introduction
       
09:00-10:30 Benefit-risk profile of medicinal products

Chair: Oscar Della Pasqua

09:00-09:30 Praveen Thokala Overview and implementation of multi criteria decision analysis (MCDA) for benefit-risk assessment
09:30-10:00 Andreas Kouroumalis European regulatory views on benefit-risk assessment methodologies - role of MCDA and other model-based approaches
10:00-10:30 Kevin Marsh Current practices and gaps in benefit-risk assessment: opportunities for combining MCDA with model-based approaches
       
10:30-12:00 Coffee break, Poster and Software session I
  Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter
       
12:00-12:40 Benefit-risk profile of medicinal products, continued

Chair: Mats Karlsson

12:00-12:20 Neeraj Gupta Model-Informed Drug Development (MIDD) for ixazomib, an oral proteasome inhibitor
12:20-12:40 Nadia Terranova Simulation analysis of absolute lymphocytes counts (ALC) and relapse rate (RR) following cladribine (re-)treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS)
       
12:40-12:45 Announcement for ACoP8 (2017)

Jin Jin

       
12:45-14:10 Lunch
       
14:10-15:10 Scaling of PD in paediatrics

Chair: Lutz Harnisch

14:10-14:50 Joseph Standing Scaling pharmacodynamics in children: Lessons from immunology, infectious diseases and critical care
14:50-15:10 Nick Holford Scaling renal function in neonates and infants to describe the pharmacodynamics of antibiotic nephrotoxicity
       
15:10-16:40 Tea break, Poster and Software session II
  Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter
       
16:40-17:20 Study design

Chair: Marylore Chenel

16:40-17:00 Hanna Silber Baumann Using pharmacokinetic simulation to guide dose escalation decisions for targeted IL2v immunocytokines
17:00-17:20 Simon Buatois Modelling approaches in dose finding clinical trial: Simulation-based study comparing predictive performances of model averaging and model selection
       
17:20-18:00 Oncology

Chair: Dinesh de Alwis

17:20-17:40 Yuri Kheifetz Model-based individual managing of thrombocytopenia during multi-cyclic chemotherapy
17:40-18:00 Jurgen Langenhorst High exposure to fludarabine in conditioning prior to allogeneic hematopoietic cell transplantation predicts impaired CD4 reconstitution and lower probability of survival
       
       

 

Thursday 8 June

 

08:30-09:50 Lewis Sheiner Student Session

Chair: Kristin Karlsson, Julia Winkler, Paolo Magni

08:30-08:55 Elisa Borella Paediatric trial design optimization using prior knowledge in combination with modelling & simulations
08:55-09:20 John Diep Host-Pathogen interactions: A mechanism-based disease progression model to describe the pathogenesis of Acinetobacter baumannii pneumonia
09:20-09:45 Morris Muliaditan Model-based rationale for drug combinations in tuberculosis
09.45-09.50 Presentation of Lewis Sheiner student session awards
       
09:50-11:20 Coffee break, Poster and Software session III
  Posters in Group III (with poster numbers starting with III-) are accompanied by their presenter
       
11:20-12:20 Estimation methods

Chair: France Mentré

11:20-12:00 Tutorial
11:20-12:00 Robert Leary An overview of non-parametric estimation methods used in population analysis
       
12:00-12:20 Mats Karlsson A comparison of performance between parametric and nonparametric estimation for nonlinear mixed-effects models
       
12:20-12:25 Announcement for WCoP 2020

Stacey Tannenbaum

       
12:25-13:45 Lunch
       
13:45-14:45 European regulatory issues

Chair: Susan Cole & Frederike Lentz

13:45-14:15 Kristin Karlsson Regulatory pharmacometrics in the EU in practice and the role of the Modelling and Simulation Working Group
14:15-14:45 Anna Nordmark The new draft EMA Guidance on PBPK – The qualification of the intended use concept
       
14:45-16:15 Tea break, Poster and Software session IV
  Posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter
       
16:15-17:40 Stuart Beal Methodology Session dedicated to the memory of Matt Hutmacher

Chair: Emmanuelle Comets & Siv Jönsson

16:15-16:20   In memoriam Matt Hutmacher
16:20-16:40 Wojciech Krzyzanski Correction of the likelihood function as an alternative for imputing missing covariates
16:40-17:00 Henrik Bjugård Nyberg SADDLE_RESET: more robust parameter estimation with a check for local practical identifiability
17:00-17:20 Dmitry Onishchenko Joint modeling of overall survival and tumor size dynamics in non-small cell lung cancer: Clinical trial simulations and validation of predictions at study and subject levels
17:20-17:40 Eva Germovsek Handling frequent observations of composite scores: Application to PROs in COPD
       
19:00-01:00 Social event
       

 

Friday 9 June

 

09:00-10:00 Systems pharmacology

Chair: Anna Nordmark & Siv Jönsson

09:00-09:20 Markus Krauß Translational systems pharmacology for acquisition of knowledge and prediction of drug pharmacokinetics across patient populations
09:20-09:40 Robin Michelet PBPK modeling of propofol using the middle out approach
09:40-10:00 Miro Eigenmann Therapeutic antibody concentrations at the biophase
       
10:00-10:25 Modelling experience!

Chair: Katya Gibiansky

10:00-10:25 Alan Maloney The 6 biggest pharmacometrics modelling mistakes!
       
10.25-10.30 Preview of PAGE 2018
       
10:30-11:15 Coffee break and Software session
       
11:15-12:15 Infection

Chair: Lena Friberg

11:15-11:35 Richard Höglund Pharmacokinetic-pharmacodynamic modelling of artesunate in patients with drug resistant and sensitive malaria
11:35-11:55 Salvatore D'Agate Model-based screening of compounds for the treatment of Chagas disease, a neglected tropical disease
11:55-12:15 Carolina Llanos-Paez Balancing efficacy and reduction in renal function to optimize initial gentamicin dosing in children with cancer
       
12.15-12.25 Closing remarks
       
12:25-12:40 Audience input for potential PAGE2018 topics